Drug Shortage Report for TEVA-ABACAVIR/LAMIVUDINE
Report ID | 147699 |
Drug Identification Number | 02416662 |
Brand name | TEVA-ABACAVIR/LAMIVUDINE |
Common or Proper name | ABACAVIR/LAMIVUDINE 600/300MG TAB |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | LAMIVUDINE ABACAVIR |
Strength(s) | 300MG 600MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30 |
ATC code | J05AR |
ATC description | DIRECT ACTING ANTIVIRALS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2021-10-20 |
Estimated end date | 2021-12-31 |
Actual end date | 2021-12-14 |
Shortage status | Resolved |
Updated date | 2021-12-17 |
Company comments | Short dated lots |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2021-12-17 | French | Compare |
v5 | 2021-12-17 | English | Compare |
v4 | 2021-11-18 | French | Compare |
v3 | 2021-11-18 | English | Compare |
v2 | 2021-10-21 | French | Compare |
v1 | 2021-10-21 | English | Compare |
Showing 1 to 6 of 6